Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +55

Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued As FDA Approval ...

AI-generated analysis

📊 Bristol-Myers Squibb (BMY) is estimated to be 46.3% undervalued based on a Discounted Cash Flow model projecting an intrinsic value of approximately $119 per share.

📈 The stock has delivered a strong 38.1% return over the past year, though recent gains have not fully eliminated potential upside according to current valuation signals.

💊 The FDA granted accelerated approval for ZENBEXUS to treat multiple myeloma, providing a new revenue stream and supporting future cash flow projections.

🏗️ The company plans to construct a US$2.3 billion manufacturing campus in Houston to support production capabilities.

⚖️ A revived legal dispute concerning Celgene contingent value rights poses a potential financial risk with an exposure of approximately US$6.7 billion.

📉 BMY trades at a P/E ratio of 14.0x, which is below the industry average of 16.9x and far below the peer group average of 58.4x.

⏳ Upcoming patent cliffs for major drugs like Eliquis (generic in 2028) and Opdivo present risks to long-term revenue growth due to generic and biosimilar competition.

🎯 The DCF model assumes last twelve month free cash flow of about US$11.5b, with projections holding steady rather than assuming aggressive expansion.

📉 Community sentiment is divided between a bull case citing breakthrough partnerships like BioNTech and a bear case warning of patent erosion risks.

Bullish Signals
  • The stock is trading at a significant discount to its estimated intrinsic value, offering a potential margin of safety for valuation-focused investors.
  • Recent share price performance shows a 38.1% gain over the past year, indicating improving market sentiment toward the company.
  • The FDA's accelerated approval of ZENBEXUS adds a new therapeutic asset to the pipeline, supporting long-term revenue expectations.
  • The planned US$2.3 billion manufacturing campus in Houston demonstrates commitment to operational capacity and future growth.
  • Current P/E multiple of 14.0x is substantially lower than both the industry average (16.9x) and peer group average (58.4x), suggesting undervaluation relative to peers.
  • The DCF model implies a fair P/E ratio of 18.2x, indicating the market is currently pricing earnings at a discount to the company's fundamental profile.
Risk Factors
  • A revived lawsuit regarding Celgene contingent value rights creates a specific legal and financial risk with an exposure of approximately US$6.7 billion.
  • Significant upcoming patent cliffs for blockbuster drugs like Eliquis (generic in 2028) and Opdivo raise the risk of generic and biosimilar competition impacting long-term revenue.
  • The DCF model assumes cash flows will broadly hold around current levels rather than aggressive expansion, which may limit upside potential if growth is slower than expected.
Full Analysis
Simply Wall St analysis suggests Bristol-Myers Squibb (BMY) stock is undervalued by approximately 46.3%, trading at $63.83 per share against a Discounted Cash Flow (DCF) intrinsic value estimate of roughly $119. The company has delivered a 38.1% gain over the past year, yet valuation metrics including P/E multiples indicate it remains cheaper than industry and peer averages. The analysis highlights specific catalysts supporting future cash flows, including the FDA's accelerated approval of ZENBEXUS for multiple myeloma and plans to build a US$2.3 billion manufacturing campus in Houston. Conversely, risks include a revived lawsuit regarding Celgene contingent value rights worth US$6.7 billion and significant upcoming patent cliffs for blockbuster drugs like Eliquis and Opdivo. Valuation comparisons show BMY trading at a P/E of 14.0x, which is below the Pharmaceuticals industry average of 16.9x and significantly lower than the peer group average of 58.4x. The model implies a fair P/E ratio of 18.2x, suggesting the market is pricing in lower earnings multiples than warranted by the company's size and profitability profile. The article concludes that while the discount may reflect genuine mispricing offering a margin of safety for investors, it could also serve as compensation for legal overhangs and patent expiries. The key determinant for future performance will be whether BMY can sustain its cash flows by offsetting revenue erosion from generic competition with its robust pipeline and strategic investments.